Orphan drugs revisited: cost–effectiveness analysis of the addition of mifamurtide to the conventional treatment of osteosarcoma

References

• European Medicines Agency (EMA). Human medicines - Mepact (mifamurtide). [Updated 6 September 2012]. Available from: www.emea.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000802/human_med_000899.jsp&mid=WC0b01ac058001d12
   Google Scholar
• Pritchard-Jones K, Kaatsch P, Steliarova-Foucher E, et al. Cancer in children and adolescents in Europe: developments over 20 years and future challenges. Eur J Cancer 2006;42(13):2183-90
   PubMed Web of Science ®Google Scholar
• Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival–a report from the Children’s Oncology Group. J Clin Oncol 2008;26(4):633-8
   PubMed Web of Science ®Google Scholar
• National Cancer Institute (NCI). Osteosarcoma and malignant fibrous histiocytoma of bone treatment. Available from: www.cancer.gov/cancertopics/pdq/treatment/osteosarcoma [Last accessed 2009]
   Google Scholar
• Picci P. Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis 2007;2:6
   PubMed Web of Science ®Google Scholar
• Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer 2009;125(1):229-34
   PubMed Web of Science ®Google Scholar
• Peris Bonet R, et al. Cáncer infantile en España. Estadísticas 1980-2011. In: Registro Nacional de Tumores Infantiles (RNTI-SEHOP). Universitat de València; Ed Valencia: 2012
   Google Scholar
• Geraci M, Birch JM, Alston RD, et al. Cancer mortality in 13 to 29-year-olds in England and Wales, 1981-2005. Br J Cancer 2007;97(11):1588-94
   PubMedGoogle Scholar
• World Health Organisation (WHO). Global Health Observatory/WHOSIS. Available from: www.who.int/whosis/mort/download/en/index.html [Last accessed 2009]
   Google Scholar
• Longhi A, Errani C, De PM, et al. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 2006;32(6):423-36
   PubMed Web of Science ®Google Scholar
• Automated Childhood Cancer Information System. Osteosarcoma incidence and survival by registry and tumour. Available from: www-dep.iarc.fr/accis/data.htm [Last accessed 2009]
   Google Scholar
• Wilkins RM, Cullen JW, Odom L, et al. Superior survival in treatment of primary nonmetastatic pediatric osteosarcoma of the extremity. Ann Surg Oncol 2003;10(5):498-507
   PubMedGoogle Scholar
• Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005;23(9):2004-11
   PubMed Web of Science ®Google Scholar
• Redondo A, Cruz J, Lopez-Pousa A, Barón F. SEOM clinical guidelines for the treatment of osteosarcoma in adults-2013. Clin Transl Oncol 2013;15(12):1037-43
   PubMedGoogle Scholar
• Brosa M, Gisbert R, Rodríguez JM y Soto J. Principios, métodos y aplicaciones del análisis del impacto presupuestario en el sector sanitario. Pharmacoeconomics Spanish Res Articles 2005;2(2):64-78
   Google Scholar
• Ferrari S, Briccoli A, Mercuri M, et al. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol 2003;21(4):710-15
   PubMed Web of Science ®Google Scholar
• López-Bastida J, Oliva J, Antoñanzas F, et al. Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ 2010;11(5):513-20
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Discounting of health benefits in special circumstances. Available from: www.nice.org.uk/media/955/4F/Clarification_to_section_5.6_of_the_Guide_to_Methods_of_Technology_Appraisals.pdf
   Google Scholar
• Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res 2009;152:3-13
   PubMedGoogle Scholar
• Real Decreto Ley 8/2010 de 20 de mayo, por el que se adoptan medidas extraordinarias para la reducción del déficit público In: Boletín oficial del estado. 126:45070-128.Spain: 2010
   Google Scholar
• McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J 2006;26:154-8
   PubMedGoogle Scholar
• Jeys LM, Grimer RJ, Carter SR, et al. Post operative infection and increased survival in osteosarcoma patients: are they associated? Ann Surg Oncol 2007;14(10):2887-95
   PubMed Web of Science ®Google Scholar
• MacEwen EG, Kurzman ID, Rosenthal RC, et al. Therapy for osteosarcoma in dogs with intravenous injection of liposome encapsulated muramyl tripeptide. J Natl Can Inst 1989;81:935-8
   PubMed Web of Science ®Google Scholar
• Schulz G, Cheresh DA, Varki NM, et al. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res 1984;44(12 Pt 1):5914-20
   PubMed Web of Science ®Google Scholar
• Navid F, Santana VM, Barfield RC. Anti-GD2 antibody therapy for GD2-expressing tumors. Curr Cancer Drug Targets 2010;10(2):200-9
   PubMed Web of Science ®Google Scholar
• Yu AL, Gilman AL, Ozkaynak MF, et al. Children’s Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010;363(14):1324-34
   PubMed Web of Science ®Google Scholar
• Park JR, Bagatell R, London WB, COG Neuroblastoma Committee. Children’s Oncology Group’s 2013 blueprint for research: neuroblastoma. Pediatr Blood Cancer 2013;60(6):985-93
   PubMed Web of Science ®Google Scholar
• Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008;14(11):1264-70
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Appraising Orphan Drugs. Available from: www.nice.org.uk/niceMedia/pdf/smt/120705item4.pdf
   Google Scholar
• Ministerio de Sanidad y Política Social (MSPS). El Ministerio de Sanidad y Consumo incluye en la financiación pública dos nuevos medicamentos para enfermedades raras. Available from: www.msps.es/gabinetePrensa/notaPrensa/desarrolloNotaPrensa.jsp?id=1421
   Google Scholar
• European Medicines Agency (EMA). Medicines for rare diseases, 2011. Available at www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/general/general_content_000034.jsp&mid=WC0b01ac058002d4eb
   Google Scholar
• Orofino J, Soto J, Casado MA, Oyagüez I. Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007. Appl Health Econ Health Policy 2010;8(5):301-15
   PubMedGoogle Scholar
• Lewis IJ, Nooij MA, Whelan J, et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 2007;99(2):112-28
   PubMed Web of Science ®Google Scholar
• Instituto Nacional de Estadística - INE. Tablas de mortalidad de la población de España 1991-2008. Available from: www.ine.es/jaxi/tabla.do?path=/t20/p319a/serie/l0/&file=01001.px&type=pcaxis&L=0 [Last accessed 17 June 2010]
   Google Scholar
• CGCOF (Consejo General del Colegio Oficial de Farmacéuticos) 2011. Available from: www.portalfarma.com [Last accessed December 2011]
   Google Scholar
• E-Salud. Base de datos de costes sanitarios españoles (2011). Oblikue Consulting. Available from: www.oblikue.com/bddcostes/ [Last accessed December 2011]
   Google Scholar
• Ministerio de sanidad, política social e igualdad. Portal estadístico. Available from: www.msps.es/estadEstudios/estadisticas/sisInfSanSNS/home.htm [Last accessed December 2011]
   Google Scholar
• Burls A, Austin D, Moore D. Commissioning for rare diseases: view from the frontline. BMJ 2005;331(7523):1019-21
   PubMedGoogle Scholar
• Gildea TR, Shermock KM, Singer ME, Stoller JK. Cost-effectiveness analysis of augmentation ther-apy for severe alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2003;167(10):1387-92
   PubMed Web of Science ®Google Scholar
• García Quetglas E, Azanza Perea JR, Lecumberri Villame-diana R. New therapeutic strategies for Mieloma múltiple. Efficacy and cost-effectiveness analyses. Med Clin (Barc) 2008;130(16):626-35
   PubMedGoogle Scholar
• Cannock M, Wang D, Fry-Smith A, Moore D. Prevalence and prognosis of paroxysmal nocturnal haemoglobinurea and the clinical and cost-effectiveness of eculizumab [Report Number 69]. Birmingham (UK): University of Birmingham; 2008. Available from: www.rep.bham.ac.uk/2008/PNH.pdf
   Google Scholar
• Hoyle M, Green C, Thompson-Coon J, et al. Cost-effectiveness of temsiro-limus for first line treatment of advanced renal cell carcinoma. Value Health 2010;13(1):61-8
   PubMedGoogle Scholar
• Paz-Ares L, García del Muro X, Grande E, et al. Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumors (GIST) after progression or intolerance with imatinib. Clin Transl Oncol 2008;10(12):831-9
   PubMed Web of Science ®Google Scholar
• Maroto P, Villavicencio H, Piñol C, et al. Análisis coste-efectividad de sorafenib oral en el tratamiento del carcinoma de células renales avanzado. Rev Esp Econ Salud 2008;7(4):173-80
   Google Scholar